| II-04 Eleni Alexopoulou Population pharmacokinetics of budesonide (BDS) and its two main metabolites 6β-hydroxy-budesonide(6OH-BDS) and 16α-hydroxy-prednisolone(16OH-PREDN) with and without hyperhydration effect Wednesday 15:35-17:00 |
| II-06 Simon Arsène In silico trials platform for exploration of trial design space in atopic dermatitis Wednesday 15:35-17:00 |
| II-07 Peter Ashcroft Mechanistic PKPD modelling of targeted protein degradation to improve compound selection in drug discovery and translation to the clinic Wednesday 15:35-17:00 |
| II-08 Rami Ayoun Alsoud Model-based interspecies scaling and impact of anti-drug antibodies on the pharmacokinetics of the therapeutic protein CB 4332 Wednesday 15:35-17:00 |
| II-09 Nicolas Azzopardi Mechanistic model of oxytocin/vasopressin-stimulated GPCR. Wednesday 15:35-17:00 |
| II-11 Pavel Balazki 4ß-OH Cholesterol as endogenous biomarker for CYP3A4 inducer DDI studies – a PBPK-QSP platform for in silico compound testing Wednesday 15:35-17:00 |
| II-12 Catalina Barcelo Use of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis Wednesday 15:35-17:00 |
| II-13 Roberta Bartolucci Exposure-Response Analysis of the Macitentan Effects on NT-proBNP and WHO functional class in adult patients with Pulmonary Arterial Hypertension Wednesday 15:35-17:00 |
| II-16 Davide Bindellini Understanding the physiology of the hypothalamic-pituitary-adrenal axis to optimise cortisol replacement therapy: A quantitative modelling framework Wednesday 15:35-17:00 |
| II-22 Núria Buil Bruna Understanding onset and extent of response using different clinical endpoints in Atopic Dermatitis Wednesday 15:35-17:00 |
| II-26 JunSeok Cha A Pharmacokinetic/Pharmacodynamic Model of Recombinant Batroxobin Wednesday 15:35-17:00 |
| II-28 Wendy Chu Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa Wednesday 15:35-17:00 |
| II-30 Michael Cloesmeijer Physiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen Wednesday 15:35-17:00 |
| II-31 Aude Coumau Population pharmacokinetic modelling to characterize (es)citalopram exposure in a large cohort of psychiatric patients Wednesday 15:35-17:00 |
| II-34 Anna Dari Mechanistic Modeling Projections of Antibody Persistence After Homologous Booster Regimens of COVID-19 Vaccine Ad26.COV2.S in Humans Wednesday 15:35-17:00 |
| II-36 Wilbert de Witte Whole-body PBPK with tissue TMDD modelling to predict determining parameters of target occupancy in tissues Wednesday 15:35-17:00 |
| II-40 Qian Dong Population pharmacokinetic analysis of nonlinear behavior of adefovir Wednesday 15:35-17:00 |
| II-42 Janna Duong A dermal physiologically-based pharmacokinetic (PBPK) model of clobetasol propionate to predict systemic exposure in eczema and dermatitis patients Wednesday 15:35-17:00 |
| II-44 Jacqueline Ernest A translational site-of-action PK-PD modeling platform to propose treatment shortening regimens for tuberculosis Wednesday 15:35-17:00 |
| II-46 Undine Falkenhagen Can quantitative systems pharmacology guide precision dosing? An illustrative warfarin-INR example Wednesday 15:35-17:00 |
| II-47 Alan Faraj A model for evaluation of novel on-demand treatment of bleeding events in hemophilia subjects Wednesday 15:35-17:00 |
| II-48 Anna Fochesato A minimal PBPK model to unveil anti-tuberculosis drug distribution in pulmonary lesions: a blueprint for improving efficacy screenings. Wednesday 15:35-17:00 |
| II-49 Sylvaine Galiegue Derisking the development of rilzabrutinib, a BTK inhibitor currently in phase III, with a PBPK model in lieu of some clinical studies Wednesday 15:35-17:00 |
| II-50 María García-Cremades Risk stratification algorithm for MDR-TB patients based on pooled individual data analysis. Wednesday 15:35-17:00 |
| II-51 Maite Garraza Obaldia Semi-mechanistic model of the Haemodynamic effects of propofol and remifentanil administered in combination to patients undergoing general anaesthesia Wednesday 15:35-17:00 |
| II-52 Frédéric Gaspar Population pharmacokinetics of apixaban in a real-life hospitalized population Wednesday 15:35-17:00 |
| II-53 Amira Ghoneim Modeling of the Pharmacokinetics of the Selective Orexin-1 Receptor Antagonist ACT-539313 with Auto-Inhibition Wednesday 15:35-17:00 |
| II-54 Audrick GIBERT PK/PD of unfractionned heparin during cardiopulmonary bypass: an individual patient data meta-analysis of two studies Wednesday 15:35-17:00 |
| II-62 Yannick Hoffert An automated multi-model selection algorithm to improve precision dosing of tacrolimus in liver, lung, and bowel transplant recipients Wednesday 15:35-17:00 |
| II-63 Ana Homšek Population pharmacokinetic model of infliximab in patients with fistulising Crohn’s disease Wednesday 15:35-17:00 |
| II-64 Vincent Hurez Development of a primary Sjogren’s Syndrome (pSS) quantitative systems pharmacology (QSP) model linking mechanistic pathways to clinical scores. Wednesday 15:35-17:00 |
| II-69 SEONGMEE JEONG Human effective dose prediction of analgesic drug using translational PK-PD modeling Wednesday 15:35-17:00 |
| II-71 Soo-Min Jung Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Nesuparib (JPI-547) in Patients with Advanced Solid Tumor Wednesday 15:35-17:00 |
| II-73 Atefeh Kazeroonian A first-ever mechanistic disease model of IgG4-related disease identifies high-potential therapy targets Wednesday 15:35-17:00 |
| II-74 heungjo Kim Population pharmacokinetics of intravenous midazolam in critically ill patients supported with extracorporeal membrane oxygenation therapy Wednesday 15:35-17:00 |
| II-75 Bastian Kister Quantitative Systems Pharmacology of Interferon Alpha Administration and its induced cellular response in mice Wednesday 15:35-17:00 |
| II-76 Christine Juliane Kleist A PKPD model of favipiravir and ribavirin in Lassa virus infected mice Wednesday 15:35-17:00 |
| IV-17 Jane Knöchel Using semi-mechanistic modelling to inform the design of the Ph3 program for a novel PCSK9 antisense oligonucleotide Thursday 15:25-16:55 |
| IV-18 Julia Korell Population Pharmacokinetic Model for BI 1015550 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis Thursday 15:25-16:55 |
| IV-20 Shaun Kumar Empirical Population Pharmacodynamic Models for beti-cel for the Treatment of Patients with β-Thalassemia who Require Regular Transfusions. Thursday 15:25-16:55 |
| IV-22 Mun Kyungran Development of User-Friendly Bayesian Predictive Platform for Blood Boron-10 Pharmacokinetics following Intravenous Infusion of [10B] L-4-BORONOPHENYLALANINE Thursday 15:25-16:55 |
| IV-23 Jennifer Lang Development of a semi-mechanistic pharmacokinetic/pharmacodynamic model of a small interfering RNA targeting liver proteins in mice and cynomolgus monkeys Thursday 15:25-16:55 |
| IV-27 Moon Hee Lee First-in-Human Dose Selection for TU7710 through Pharmacokinetic and Pharmacodynamic Modeling and Simulation Thursday 15:25-16:55 |
| IV-29 Letao Li Preeclampsia increases maternal exposure to betamethasone in pregnancy: a population pharmacokinetic study Thursday 15:25-16:55 |
| IV-31 Hyeong-Seok Lim Translational pharmacokinetic-pharmacodynamic modeling and simulation to predict efficacious human doses for YH35324 (GI-301) Thursday 15:25-16:55 |
| IV-32 Klaus Lindauer Allometric Scaling for Efficacious First-in-Human Dose Prediction of Pharmacologically-Active Parent and Metabolite Based on Rat, Dog and Monkey PK data Thursday 15:25-16:55 |
| IV-33 Carolina Llanos-Paez Extended model-based meta-analysis of joint longitudinal FEV1 and exacerbation rate in randomized COPD trials Thursday 15:25-16:55 |
| IV-36 Julia Macente Physiologically-based Pharmacokinetics modelling to predict the systemic exposure of medicines in infants via breastmilk: a contribution from the ConcePTION Project. Thursday 15:25-16:55 |
| IV-38 Eleonora Marostica Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients Thursday 15:25-16:55 |
| IV-43 Nina Nauwelaerts Physiologically Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to medicines: a contribution from the ConcePTION Project Thursday 15:25-16:55 |
| IV-47 Marije Otto Evaluation of Darigabat QTc Prolongation in Healthy Volunteers: a Concentration-QTcF Analysis Thursday 15:25-16:55 |
| IV-48 Agustos Cetin Ozbey Physiologically based pharmacokinetic modelling of the impact of hepatic impairment on glucuronidation – a case study with midazolam. Thursday 15:25-16:55 |
| IV-49 Seongwon Park Evidence-based evaluation for race difference of pirfenidone using population pharmacokinetics model |
| IV-50 Suemin Park Exposure-Response Analysis Using Time to Event Data for Bevacizumab Biosimilar, SB8 and the Reference Bevacizumab Thursday 15:25-16:55 |
| IV-52 Blaise Pasquiers Rituximab in Anti‑Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: population pharmacokinetic modeling and simulations of alternative doses in under-exposed patients Thursday 15:25-16:55 |
| IV-53 Christoph Pfaffendorf A combined population pharmacokinetic model of proguanil and its active metabolite cycloguanil in infants to adults with uncomplicated malaria Thursday 15:25-16:55 |
| IV-55 Thao- Nguyen Pham Effect brain irradiation with X-ray/Proton beam on circulating immune cell in rodents: A longitudinal modeling approach Thursday 15:25-16:55 |
| IV-64 Gledys Reynaldo Fernandez Enlightenment the strategic selection of pegylated rHuEPO candidates using a mechanistic model- driven extrapolation approach of the pharmacokinetics and pharmacodynamics. Thursday 15:25-16:55 |
| IV-65 Karine Rodriguez-Fernandez Individualized dosing regimen optimization using a population pharmacokinetic-pharmacodynamic model for secukinumab in clinical practice psoriatic patients Thursday 15:25-16:55 |
| IV-68 Medhat M. Said Disease-drug-drug interaction in drug repurposing of intravenous imatinib for COVID-19 ARDS Thursday 15:25-16:55 |
| IV-69 Eric Salgado Target engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS) Thursday 15:25-16:55 |
| IV-71 Darlene Santiago External Validation of Population PK and PD Models for Characterizing the Impact of CYP2C9 and VKORC1 Genotypes in the Management of Warfarin Therapy in Caribbean Hispanic Patients. Thursday 15:25-16:55 |
| IV-76 Stef Schouwenburg A pooled population pharmacokinetic study of oral and intravenous clavulanic acid in neonates Thursday 15:25-16:55 |
| IV-80 Carsten Terjung Modeling PK and PK/PD in of anti-VEGF agents in a preclinical rabbit model of VEGF-induced retinal hyperpermeability Thursday 15:25-16:55 |
| IV-81 Thi Quyen Tran Model-based meta-analysis of relationship between pioglitazone and histological outcomes in non-alcoholic steatohepatitis patients Thursday 15:25-16:55 |
| IV-83 Pieter Van Brantegem Longitudinal time to positivity is unable to predict clinical outcome for drug susceptible tuberculosis Thursday 15:25-16:55 |
| IV-85 Coen van Hasselt Integrative pharmacokinetic model for esketamine and its metabolite esnorketamine Thursday 15:25-16:55 |
| IV-87 Sander van Tilburg Population pharmacokinetics and pharmacodynamics of intravenous immunoglobulin treatment in patients with Guillain-Barré syndrome Thursday 15:25-16:55 |
| IV-90 Umberto Villani Model-based rationale for the in vitro characterisation of antimicrobial combinations in Buruli Ulcer Thursday 15:25-16:55 |
| IV-92 My Luong Vuong Population pharmacokinetics of fluconazole in critically ill patients: an individual patient data meta-analysis. Thursday 15:25-16:55 |
| IV-93 Zhigang Wang A repeated time-to-event model linking infliximab clearance to the risk of relapse during maintenance treatment of patients with inflammatory bowel disease Thursday 15:25-16:55 |
| IV-95 Shuying Yang Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia Thursday 15:25-16:55 |
| IV-96 Sung-yoon Yang Prediction of potential drug-drug interaction of tofacitinib and ritonavir using a population modeling approach with allometric scaling method Thursday 15:25-16:55 |
| IV-97 Janice Zhang Mechanism-based pharmacokinetic-pharmacodynamic modeling of short-term erythroferrone response and long-term efficacy of erythropoietin in chemotherapy-induced anemia rats Thursday 15:25-16:55 |
| IV-98 Qiaolin Zhao Paracetamol (Acetaminophen) and Metabolites Population Pharmacokinetics Model in children and adults with Spinal Muscular Atrophy Thursday 15:25-16:55 |
